Typhoid Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
New vaccine SKYTyphoid receives WHO prequalification, boosting global health
independantexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from independantexpress.com Daily Mail and Mail on Sunday newspapers.
Typhoid vaccine, SKYTyphoid, licensed for export by Korea
outbreaknewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outbreaknewstoday.com Daily Mail and Mail on Sunday newspapers.
Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study
Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal.
The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®.
Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT.
IVI-SK s new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal
December 17, 2020 - SEOUL, South Korea - Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®.
Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT.
vimarsana © 2020. All Rights Reserved.